Intercept Pharmaceuticals (NASDAQ: ICPT) has recently received a number of price target changes and ratings updates:

  • 11/26/2016 – Intercept Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $224.00 price target on the stock.
  • 11/18/2016 – Intercept Pharmaceuticals had its “neutral” rating reaffirmed by analysts at FBR & Co. They wrote, “At the annual meeting of the AASLD (American Association for the Study of Liver Diseases) held in Boston, Massachusetts, November 11–15, Intercept Pharmaceuticals and its collaborators presented results from three post-hoc analyses of the completed POISE Phase III trial with Ocaliva in patients with primary biliary cholangitis (PBC). In parsing through the analyses presented, we came away with a more definitive picture of the wealth of data generated by POISE, which is the pivotal trial that gained Ocaliva FDA approval in May 2016. Importantly, the analyses provide data that may be added to the compendium of information that supports Ocaliva’s nascent potential in PBC.””
  • 11/18/2016 – Intercept Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $350.00 price target on the stock.
  • 11/15/2016 – Intercept Pharmaceuticals had its “buy” rating reaffirmed by analysts at Cowen and Company.
  • 11/11/2016 – Intercept Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $224.00 price target on the stock.
  • 11/7/2016 – Intercept Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Robert W. Baird. They now have a $332.00 price target on the stock.
  • 11/6/2016 – Intercept Pharmaceuticals had its “buy” rating reaffirmed by analysts at JMP Securities.
  • 11/3/2016 – Intercept Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $350.00 price target on the stock.
  • 11/3/2016 – Intercept Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $224.00 price target on the stock.
  • 11/2/2016 – Intercept Pharmaceuticals had its “buy” rating reaffirmed by analysts at Cowen and Company. They now have a $225.00 price target on the stock.
  • 11/2/2016 – Intercept Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Intercept received a major boost with the approval of its lead drug, Ocaliva, in combination with ursodeoxycholic (UDCA), for the treatment of primary biliary cholangitis (PBC) in the U.S. A potential approval in the EU around 2016 end will boost Intercept’s portfolio. The company is currently working on a commercial launch of the drug. We are also encouraged by Intercept’s efforts to develop the drug in additional indications. Estimates have been stable lately ahead of the company’s Q3 earnings release. The company has positive record of earnings surprises in the recent quarters. However, expenses will continue to rise in the coming quarters as the company prepares for a potential launch of Ocaliva. We also remain concerned about the lack of other late-stage candidates in Intercept’s pipeline.”
  • 10/26/2016 – Intercept Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $147.00 price target on the stock. According to Zacks, “Intercept received a major boost with the approval of its lead drug, Ocaliva, in combination with ursodeoxycholic (UDCA), for the treatment of primary biliary cholangitis (PBC) in the U.S. A potential approval in the EU around 2016 end will boost Intercept’s portfolio. The company is currently working on a commercial launch of the drug. We are also encouraged by Intercept’s efforts to develop the drug in additional indications. Estimates have been stable lately ahead of the company’s Q3 earnings release. The company has positive record of earnings surprises in the recent quarters. However, expenses will continue to rise in the coming quarters as the company prepares for a potential launch of Ocaliva. We also remain concerned about the lack of other late-stage candidates in Intercept’s pipeline.”
  • 10/24/2016 – Intercept Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings Inc.. They now have a $200.00 price target on the stock, down previously from $250.00.
  • 10/17/2016 – Intercept Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $239.00 price target on the stock.
  • 10/14/2016 – Intercept Pharmaceuticals had its “positive” rating reaffirmed by analysts at Leerink Swann. They now have a $159.00 price target on the stock.
  • 10/7/2016 – Intercept Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $239.00 price target on the stock.

Shares of Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) opened at 108.71 on Tuesday. The stock’s 50 day moving average price is $122.88 and its 200-day moving average price is $145.74. Intercept Pharmaceuticals Inc. has a 52-week low of $89.76 and a 52-week high of $179.61. The company’s market capitalization is $2.70 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings data on Thursday, November 3rd. The biopharmaceutical company reported ($3.59) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($3.82) by $0.23. The business earned $4.70 million during the quarter, compared to the consensus estimate of $4.77 million. Intercept Pharmaceuticals had a negative return on equity of 66.97% and a negative net margin of 3,287.95%. Intercept Pharmaceuticals’s quarterly revenue was up 1051.1% on a year-over-year basis. During the same period last year, the company earned ($2.10) earnings per share. On average, analysts expect that Intercept Pharmaceuticals Inc. will post ($15.63) earnings per share for the current year.

In other Intercept Pharmaceuticals news, insider Lisa Bright sold 155 shares of the firm’s stock in a transaction that occurred on Monday, October 3rd. The stock was sold at an average price of $163.20, for a total value of $25,296.00. Following the completion of the transaction, the insider now directly owns 18,305 shares in the company, valued at $2,987,376. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CMO David Shapiro sold 411 shares of the firm’s stock in a transaction that occurred on Monday, October 10th. The shares were sold at an average price of $153.34, for a total value of $63,022.74. Following the completion of the transaction, the chief marketing officer now owns 44,272 shares of the company’s stock, valued at $6,788,668.48. The disclosure for this sale can be found here. 9.20% of the stock is owned by company insiders.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

5 Day Chart for NASDAQ:ICPT

Receive News & Ratings for Intercept Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.